Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO)
OBIO moved a median of -0.48% 30 minutes after news, and +0.26% by the close. How OBIO actually reacts to news — the realized, point-in-time move the market made, measured across 251 labeled events over the last three years with zero look-ahead.
OBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 246 |
| 30-min | -0.48% | 40% | 251 |
| 60-min | -0.43% | 41% | 251 |
| to close | +0.26% | 52% | 248 |
| Middle 50% of OBIO reactions | -1.87% to +1.02% |
|---|---|
| Median reaction (30-min) | -0.48% |
| Measured reactions | 251 |
Half of all Orchestra BioMed Holdings, Inc. - Ordinary Shares news events land between -1.87% and +1.02% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OBIO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 20 | 0.00% | 40% | -0.06% |
| Rating reiterations | 42 | -0.13% | 41% | -0.25% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how OBIO ranks against every other measured name →
That’s how OBIO usually reacts — get an email when it moves on news →Email me when OBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OBIO's baseline. Nothing else.
Recent OBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Orchestra BioMed Holding For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | +1.28% | |
| Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy | Press release | GlobeNewswire | -0.21% | +1.28% | |
| Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026 | Press release | GlobeNewswire | -0.66% | -0.66% | |
| Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics | Press release | GlobeNewswire | -0.75% | +0.67% | |
| Form 8-K Orchestra BioMed Holding For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -2.34% | +6.05% | |
| Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.60% | -4.63% | |
| Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +2.01% | -2.29% | |
| Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference | Press release | GlobeNewswire | +0.38% | -1.81% | |
| Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes | Press release | GlobeNewswire | -2.49% | +12.83% | |
| Form 8-K Orchestra BioMed Holding For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -1.73% | |
| Form S-8 Orchestra BioMed Holding | SEC filing · Form S-8 | SEC EDGAR | -0.25% | -1.73% | |
| Form DEFA14A Orchestra BioMed Holding | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -3.75% | |
| Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -1.03% | |
| Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.63% | +0.50% | |
| Form 10-Q Orchestra BioMed Holding For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.74% | -0.25% | |
| Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | Press release | GlobeNewswire | -0.74% | -0.25% | |
| Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 | Press release | GlobeNewswire | -0.30% | +4.10% | |
| Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | Press release | GlobeNewswire | -0.74% | +1.23% | |
| Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement | Press release | GlobeNewswire | -0.74% | +1.23% | |
| FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy | Press release | GlobeNewswire | -0.52% | +3.64% | |
| Form ARS Orchestra BioMed Holding For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.52% | +3.64% | |
| Form DEF 14A Orchestra BioMed Holding For: Jun 23 | SEC filing · Form DEF | SEC EDGAR | -0.52% | +3.64% | |
| Form DEFA14A Orchestra BioMed Holding | SEC filing · Form DEFA14A | SEC EDGAR | -0.52% | +3.64% | |
| Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 | Press release | GlobeNewswire | -0.12% | -0.24% | |
| Form 10-K Orchestra BioMed Holding For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.11% | -4.99% | |
| Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update | Press release | GlobeNewswire | -0.11% | -4.99% | |
| Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT | Press release | GlobeNewswire | +0.00% | +3.56% | |
| Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences | Press release | GlobeNewswire | -1.26% | +0.00% | |
| Form 8-K Orchestra BioMed Holding For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +2.98% | +0.26% | |
| Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.98% | +0.26% | |
| Form S-8 Orchestra BioMed Holding | SEC filing · Form S-8 | SEC EDGAR | +2.56% | +0.26% | |
| Form 8-K Orchestra BioMed Holding For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -4.38% | -2.92% | |
| Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics | Press release | GlobeNewswire | -4.38% | -2.92% | |
| Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting | Press release | GlobeNewswire | +1.13% | -1.13% | |
| Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.14% | +1.14% | |
| Form 8-K Orchestra BioMed Holding For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | — | |
| Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences | Press release | GlobeNewswire | +0.67% | +9.33% | |
| Form 10-Q Orchestra BioMed Holding For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.67% | +9.33% | |
| Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates | Press release | GlobeNewswire | +0.67% | +9.33% | |
| Orchestra BioMed to Host Business Update Call on November 12, 2025 | Press release | GlobeNewswire | +1.82% | +2.60% | |
| Form S-3 Orchestra BioMed Holding | SEC filing · Form S-3 | SEC EDGAR | +1.82% | +2.60% | |
| Form 8-K Orchestra BioMed Holding For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +11.08% | |
| Form 8-K Orchestra BioMed Holding For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | -4.52% | -4.77% | |
| Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements | Press release | GlobeNewswire | -4.52% | -4.77% | |
| Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial | Press release | GlobeNewswire | -2.15% | -0.25% | |
| Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit | Press release | GlobeNewswire | +0.00% | -2.38% | |
| Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout | Press release | GlobeNewswire | +0.06% | -0.36% | |
| Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology | Press release | GlobeNewswire | +0.94% | +12.78% | |
| Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction | Press release | GlobeNewswire | +0.38% | +0.76% | |
| Form 10-Q Orchestra BioMed Holding For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.23% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OBIO section they belong to.
Where else OBIO is measured.
OBIO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Orchestra BioMed Holdings, Inc. - Ordinary Shares's median reaction calculated?
Every labeled OBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 251 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of OBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.